Canaccord Genuity Maintains Buy on BioNTech, Lowers Price Target to $132
Canaccord Genuity analyst John Newman maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $136 to $132.
Stocks · News reference
A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally
A new NIH-backed initiative to speed up personalized cancer vaccine development sent stocks like MRNA, BNTX, and NVAX surging Friday.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Why Is BioNTech Stock Falling Tuesday?
BioNTech stock drops over 5% as BNT113 mRNA cancer trial misses PFS endpoint. Focus shifts to overall survival in HPV16+ HNSCC study.
BioNTech shares are trading lower after the company announced its Phase 2/3 trial of BNT113 failed to meet a key progression-free survival endpoint in HPV16-positive head and neck cancer.
Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. futures mixed; Syndax plunged 17% after its lung fibrosis trial missed its endpoint. Zhibao, Chaince, Six Flags and tech stocks also fell premarket.
Novo Nordisk and Eli Lilly Just Got Some Fantastic News
A NIH-funded study found that the GLP-1 drug semaglutide extended lifespan and slowed aging in older mice by improving muscle and cognitive function and reducing inflammation. The findings could accelerate adoption of GLP-1 drugs from Novo Nordisk and Eli Lilly, with forecasts predicting 25 million Americans on these treatments by 2030 and a market reaching $190 billion by 2035.
9 Of 11 Sectors Rise In Friday Trading As Cyclicals Lead
Nine of 11 sectors are higher in Friday’s regular session, with cyclical sectors holding the top three positions. The leaders are separated rather than clustered, with no single gap clearly standing apart from the other breaks across the table.